SentienBiotech

Sentien Biotechnologies, Inc. is a privately owned, clinical-stage company developing novel approaches to cell therapy.

[Blaithin A. McMahon @McmahonBlaithin]

SB-101 running in series w HF1400 filter to allow sustained 24hr delivery of regenerative products from human mesenchymal stems cells (SB-101) in a COVID19 AKI pt on CRRT. A milestone for the field of stem cell research. @musc_nephrology @MUSChealth @SentienBiotech @crrtonline

[SentienBiotech @SentienBiotech]

@SentienBiotech is @alliancerm's Cell & Gene Meeting on the Mesa in Carlsbad, CA! CEO Brian Miller to present on Sentien's ex vivo MSC therapy, SBI-101, on Wednesday Oct 13 at 2:30pm. #CGMesa21 #MSC #celltherapy

[Johannes Fruehauf🇺🇦 @JFruehauf]

Congratulations @sentienbiotech team for this publication and important progress with your work. Restoring balance to the immune system through extra-corporeal treatment with stem cells. Science fiction? It’s already here!

[SentienBiotech @SentienBiotech]

@SentienBiotech reports promising results in @StemCellsTM publication on our ex vivo MSC therapy, SBI-101, for the treatment of acute kidney injury!

https://t.co/Cgp8KSg9Cb

[Madhav Swaminathan @mswami001]

Thanks to the efforts of my co-authors at @SentienBiotech and around the country!
Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation https://t.co/6M7tePIyhE

[SentienBiotech @SentienBiotech]

Read @SentienBiotech's new publication with data from our first Ph I/II study of SBI-101 in subjects with AKI! Data supports the therapeutic hypothesis that ex vivo delivery of MSC-secreted factors leads to immunomodulation & reprogramming of immune cells https://t.co/tXcwGtjFPQ

[SentienBiotech @SentienBiotech]

@SentienBiotech has received an award from @MD_Stem_Cell to help fund Sentien's clinical study of SBI-101 for the treatment of acute kidney injury associated with sepsis (including from #COVID19)! #celltherapy #MSC

[MSCRF @MD_Stem_Cell]

.@MD_Stem_Cell Research Commission Announces $1M in 3 New Awards to Accelerate Cures For:

• Primary Immunodeficiencies/Inherited Bone Marrow Failures
• Craniofacial/Bone Defects
• Sepsis/Acute Kidney Injury

Read Press Release: https://t.co/9l7vv8XSzc
#biotech #health

[SentienBiotech @SentienBiotech]

@SentienBiotech is excited to be partnering with @BARDA to evaluate our cell-based therapeutic, SBI-101, for its ability to improve clinical outcomes for patients with #sepsis, including from #COVID19! @WorldSepsisDay @SepsisAlliance

[BARDA @BARDA]

This #WorldSepsisDay, find out more about our all-of-BARDA approach to address sepsis: https://t.co/7CVl7q0nni

[SentienBiotech @SentienBiotech]

@SentienBiotech Partners with @BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis, Including from #COVID19 https://t.co/Mo0yPOs9Hb via @PRWeb

[BARDA @BARDA]

With #DRIVeInnovation support, @SentienBiotech is evaluating SBI-101, a cell based therapeutic, for its ability to improve clinical outcomes for patients with #sepsis, including #COVID19. #SolvingSepsisTogether https://t.co/T4jJUqDX8K

[SentienBiotech @SentienBiotech]

Tune in now as @SentienBiotech VP of R&D, Dr. Rita Barcia, is interviewed on ISCT TV! @ISCTglobal #COVID19 #MSC #celltherapy https://t.co/qtTXElCLdK

[SentienBiotech @SentienBiotech]

Check out @SentienBiotech's upcoming presentations at #ISCT2021! Dr. Rita Barcia, VP of R&D, will share early data from our Ph1/2 trial of SBI-101 for the treatment of severe #COVID19 & will be featured during an interview session on ISCT TV on 5/26! #celltherapy #MSC @ISCTglobal

[SentienBiotech @SentienBiotech]

Register for this webinar on Wed 4/28 with @SentienBiotech VP of R&D, Dr. Rita Barcia, discussing considerations for #MSC product and process development through clinical cGMP manufacturing, alongside other distinguished panelists! @RoosterBio @jan_nolta

[Cell & Gene Therapy @CGT_Insights]

Don't miss next week's webinar on key considerations for hMSC product and process development through clinical cGMP manufacturing (April 28th, 11am ET); https://t.co/eDHZuT9AIg @CGT_Insights #CellTherapy

[SentienBiotech @SentienBiotech]

@SentienBiotech Completes Enrollment of First Cohort in Ph 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19 https://t.co/3WF254ZGso via @PRWeb #COVID19 #celltherapy #MSC

[SentienBiotech @SentienBiotech]

@SentienBiotech's new publication highlights the ability of our ex-vivo cell therapy approach to reduce clotting in vitro, an important advantage relative to IV delivery. Particularly relevant in treating #COVID19 patients who tend to be hypercoagulable.

https://t.co/0AQqFu9kny

[SentienBiotech @SentienBiotech]

University of New Mexico physicians Dr. J. Pedro Teixeira & Dr. Christos Argyropoulos discuss enrolling the first subject in @SentienBiotech's Ph 1/2 study of SBI-101, our ex vivo MSC therapy, for the treatment of severe #COVID19! @ChristosArgyrop @NephCrit_NM @gtrejoleal

[KOAT.com @koat7news]

New experimental COVID treatment happening at UNM https://t.co/b5EMg6fVlz

[SentienBiotech @SentienBiotech]

@SentienBiotech Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19 https://t.co/oOxZ93Uggb via @PRWeb @ChristosArgyrop @NephCrit_NM @gtrejoleal #COVID19 #celltherapy #MSC

[SentienBiotech @SentienBiotech]

Check out @SentienBiotech CEO Brian Miller's presentation from the @alliancerm Cell & Gene Meeting on the Mesa!

https://t.co/gLKj8YyuZc

[SentienBiotech @SentienBiotech]

@SentienBiotech SVP of Operations @ChrisGemmiti to speak on a panel tomorrow at the Cell & Gene Therapy Bioprocessing & Commercialization virtual meeting on Strategies and Challenges in Manufacturing and Commercialization! #CGTCONF #celltherapy #MSC

https://t.co/O21TZ07Ygo